Adult case of chronic granulomatous disease with left axillary lymphadenitis caused by Mycobacterium tuberculosis var. BCG over 40 years post-vaccination: A case report
Abstract
Chronic granulomatous disease (CGD) is an inherited phagocytic dysfunction disorder. Bacillus Calmette-Guérin (BCG) vaccination is contraindicated in patients with CGD, given the risk of BCG-related infections. Notably, adverse reactions post-BCG vaccination in patients with CGD are commonly observed in childhood. In the present report, we describe the case of an adult Japanese man with CGD who developed left axillary BCG lymphadenitis at 42 years of age. The patient received the BCG vaccine at 3 months old and did not develop any childhood BCG-related disease. However, at 38 years of age, he developed a swollen left axillary lymph node. At 42 years of age, a lymph node biopsy was performed, and Mycobacterium tuberculosis var. BCG was subsequently identified. The patient was accordingly treated with antimicrobial agents for two years. Following the completion of the antimicrobial therapy, prophylaxis with interferon-gamma (IFN-γ) was administered intermittently; despite this, lymphadenitis did not relapse. This report highlights that BCG-related complications should be considered in immunocompromised patients with BCG vaccination history, even many years post-vaccination.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.